Aspire Biopharma Renames to Reflect Shift Into Industrial Manufacturing
New York, Tuesday, 8 September 2026.
Aspire Biopharma officially renamed itself Aspire-Lakewood Holdings on September 8, 2026, marking a strategic pivot into industrial manufacturing following its acquisition of automotive supplier Dura Control Systems.
The Strategic Architecture of the Rebrand
The transition to Aspire-Lakewood Holdings, Inc. was formalized on September 8, 2026, through a Certificate of Amendment filed with the Delaware Secretary of State [1]. Approved by both the board of directors and stockholders under Section 242 of the Delaware General Corporation Law, the name change reflects a fundamental shift in the company’s corporate identity following its acquisition of Dura Control Systems Corp. (DCSC) [1]. While the company’s organizational architecture has been redesigned to support a diversified holding structure, the public trading of its common stock continues under the existing NASDAQ ticker symbol, ASBP, requiring no administrative action from current stockholders [1]. According to Chief Executive Officer Kraig Higginson, the new holding company structure better aligns the corporate framework with its expanded focus as a high-volume, diversified enterprise [1].
Dura Control Systems as the Growth Engine
The acquisition of Dura Control Systems Corp. (also referred to as DCS) serves as the cornerstone of this corporate evolution [1][2]. Purchased for $30.0 million in cash, DCSC operates as a tier-one automotive supplier for major original equipment manufacturers (OEMs), utilizing 11 global manufacturing facilities and holding a portfolio of over 310 patents [1][2]. The subsidiary specializes in powertrain-agnostic technologies, including mechatronic actuators, human-machine interfaces, industrial cables, and cable control systems [1]. Financially, DCS represents a massive scaling of Aspire’s business operations; the unit reported $209.5 million in revenue and $22.3 million in Adjusted EBITDA for the fiscal year 2025, followed by $103.9 million in revenue and $10.5 million in Adjusted EBITDA for the six-month period ending June 30, 2026 [2].
Financing and Capital Restructuring
To fund the $30.0 million acquisition of DCS, Aspire utilized a $22.5 million senior secured revolving credit facility coupled with cash on hand [2]. This transaction was supported by broader capital restructuring efforts throughout 2026, including a $21.0 million private placement of Series A Convertible Preferred Stock [2]. This private placement was completed in two tranches: the first closed on February 6, 2026, raising $11.0 million, and the second closed on April 15, 2026, raising $10.0 million [2]. Additionally, the company issued convertible promissory notes with a face value of $3,750,000, which were sold for $3,000,000 after accounting for a 20% discount, representing a cash inflow of 3.000 million [2]. These capital initiatives helped the company meet the Nasdaq Capital Market’s requirement of maintaining more than $2.5 million in stockholders’ equity [2].
Navigating Nasdaq Listing and Share Consolidation
The strategic pivot into industrial manufacturing comes after a challenging period of regulatory compliance issues [2]. Aspire previously faced delisting warnings from Nasdaq starting on April 16, 2025, for failing to maintain a minimum bid price of $1.00 and a Market Value of Listed Securities (MVLS) of at least $50,000,000 [2]. In response, the company enacted a series of reverse stock splits to consolidate its share structure, including a 1-for-30 reverse split on January 16, 2026, followed by a 40-for-1 reverse split on May 11, 2026 [2]. These consecutive splits heavily impacted outstanding instruments; for instance, public warrants originally issued on February 23, 2022, with an initial exercise price of $11.50, saw their exercise price adjust to $13,800 per share, calculated as 13800 [2].